

Assessment of Serum level of Apolipoprotein E4 in Patients with Vitiligo: A Comparative Review

Asmaa.M.Qasim¹, Essam.M.Aql¹, Omnia.A.Abdallah² and Ghada.M.Khalik¹

¹Dermatology, Venereology and Andrology Dept., Faculty of Medicine, Benha University

²medical biochemistry and molecular biology Dept., Faculty of Medicine, Benha University

E-mail: birdybutterfly279@gmail.com

Abstract

Background: Vitiligo is an acquired autoimmune disorder characterized by patchy depigmentation in the skin and hair. Dysregulation of lipid metabolism and immune dysregulation are key factors in the pathogenesis of vitiligo. Apolipoprotein E4 (ApoE4), a protein involved in lipid metabolism, has been implicated in various health conditions. Assessing serum levels of ApoE4 in patients with vitiligo may provide insights into the disease process and clinical implications. **Objective:** The review aims to explore the potential role of ApoE4 in vitiligo pathogenesis, its association with lipid metabolism and immune dysregulation, and the clinical implications of altered ApoE4 levels. **Conclusions:** In conclusion, the assessment of serum levels of Apolipoprotein E4 (ApoE4) in patients with vitiligo holds promise as a potential avenue for understanding the disease and its clinical implications.

Keywords: Vitiligo; Apolipoprotein E4; Lipid Metabolism; Immune Dysregulation; Diagnostic Biomarker; Prognostic Biomarker.

1. Introduction

Vitiligo is an acquired, idiopathic, auto-immune condition characterised by patchy depigmentation of the skin, hair, or both. This illness affects a considerable fraction of the worldwide population, with an estimated frequency among adults and children of 0.5-2 %. Vitiligo is characterised by the emergence of amelanotic, milky white macules or patches with well-defined boundaries, surrounded by unaffected skin [1].

It is largely thought that vitiligo is caused by a mix of genetic, environmental, and immune factors. Recent study has given light on the possible role of lipid metabolism in vitiligo's aetiology. Lipids, such as cholesterol and different lipoproteins, are essential for cellular function and signalling pathways. Several autoimmune and inflammatory illnesses have been linked to disturbances in lipid metabolism, making it an appealing field of research for vitiligo [2].

Particularly intriguing is the interaction between oxidative stress, autoimmunity, and lipid metabolism in vitiligo. Vitiligo has been linked to oxidative stress, which is defined by the formation of reactive oxygen species (ROS) inside cells. Excessive ROS may damage DNA, proteins, and lipids, resulting in malfunction and death of cells. This oxidative assault induces the production of damage-associated molecular patterns (DAMPs) or autoantigens, therefore starting immunological responses that lead to the demise of melanocytes, the pigment-producing cells responsible for skin pigmentation [3].

In recent years, vitiligo-related research has concentrated on finding relevant biomarkers and genetic variables. ApoE4, a protein implicated in lipid metabolism, has emerged as a possible

contender for elucidating the condition. ApoE is generated in the liver and locally in the brain. It plays an important function in lipid transport and metabolism, especially in the clearance of cholesterol and other lipoproteins from the circulation [4].

There are three common versions of the ApoE gene, known as alleles: ApoE2, ApoE3, and ApoE4. The ApoE4 allele has been linked with an increased prevalence of many illnesses, including cardiovascular disease, Alzheimer's disease, and age-related cognitive decline. ApoE4 allele presence dramatically affects lipid metabolism and cholesterol homeostasis, which may contribute to systemic inflammation and oxidative stress [5].

Given the growing evidence suggesting the involvement of lipid metabolism and oxidative stress in vitiligo, investigating the serum levels of ApoE4 in patients with vitiligo holds promise. Assessing the serum levels of ApoE4 could provide valuable insights into the potential role of lipid metabolism in the pathophysiology of vitiligo, as well as its association with systemic inflammation and oxidative stress. Moreover, understanding the relationship between ApoE4 and vitiligo may offer new perspectives on diagnostic markers, therapeutic targets, and personalized treatment strategies for this challenging and complex condition [6].

This review aims to assess the potential association between ApoE4 and vitiligo, explore its role in lipid metabolism, oxidative stress, and autoimmune processes, and discuss its implications for the pathogenesis, diagnosis, and treatment of vitiligo.

2. Apolipoprotein E4:

ApoE4 is a protein that plays an essential function in lipid metabolism and is related with a variety of health disorders (Fig. (1)). This protein is encoded by the ApoE gene on chromosome 19. ApoE2, ApoE3, and ApoE4 are three frequent

variations or alleles of the ApoE gene. Due to its probable role in lipid homeostasis and its consequences for a number of diseases, ApoE4 has garnered the most interest [7]. **Table 1**




Fig. (1) Structure of Apolipoprotein E4 [8].

Table (1) Apolipoprotein E4 (ApoE4) in Lipid Metabolism and Association with Health Conditions [9].

	Description
Apolipoprotein E4 (ApoE4)	ApoE4 is a protein involved in lipid metabolism and associated with various health conditions.
Role in Lipid Metabolism	<ul style="list-style-type: none"> - Synthesized by the liver and involved in lipid transport and metabolism. - Acts as a ligand for receptors involved in the clearance of lipoproteins, particularly very low-density lipoproteins (VLDL) and remnants of chylomicrons and VLDL.
Association with Health Conditions	<ul style="list-style-type: none"> - Facilitates transportation and redistribution of lipids among tissues and organs. - ApoE4 is associated with an increased risk of cardiovascular disease, including coronary artery disease, atherosclerosis, and elevated plasma cholesterol levels. - Also linked to an increased risk of Alzheimer's disease, cognitive decline with aging, and other neurodegenerative disorders.
Mechanisms	<ul style="list-style-type: none"> - ApoE4 may influence lipid metabolism, vascular function, and inflammation, contributing to the development of associated health conditions.
Genetic Characteristics	<ul style="list-style-type: none"> - Impaired clearance of lipoproteins may lead to dyslipidemia and increased accumulation of cholesterol and triglycerides in tissues. - Promotes inflammation, oxidative stress, and vascular dysfunction. - ApoE gene has three common alleles: ApoE2, ApoE3, and ApoE4. - ApoE4 allele is characterized by the presence of cysteine residues at positions 112 and 158.
Functional Characteristics	<ul style="list-style-type: none"> - Reduced binding affinity for lipoprotein receptors compared to other ApoE isoforms. - Impaired lipoprotein clearance associated with ApoE4 increases cardiovascular risk. - Besides lipid metabolism, ApoE4 is involved in synaptic plasticity, neuronal repair, and clearance of amyloid-beta in Alzheimer's disease. - Specific mechanisms through which ApoE4 influences these processes are still under investigation. - ApoE4's role in disease susceptibility is likely influenced by interactions between genetic, environmental, and lifestyle factors.
Role in Lipid Metabolism:	ApoE4 is synthesized by the liver and is involved in lipid transport and metabolism. It

functions as a ligand for receptors involved in the uptake and clearance of lipoproteins, particularly very low-density lipoproteins (VLDL) and remnants of chylomicrons and VLDL (Fig. (2)). ApoE4 facilitates the transportation and redistribution of lipids,

including cholesterol and triglycerides, among different tissues and organs. By promoting the clearance of lipoproteins from the bloodstream, ApoE4 helps maintain lipid homeostasis and plays a role in regulating plasma lipid levels [10].




Fig. (2) ApoE4 Impairs Neuron-Astrocyte Coupling of Fatty [11].

Association with Health Conditions:

The presence of the ApoE4 allele has been linked to an elevated risk of several diseases. Epidemiological studies have repeatedly linked ApoE4 to an increased incidence of cardiovascular disease, such as coronary artery disease, atherosclerosis, and elevated plasma cholesterol levels. ApoE4 has also been linked to an increased risk of Alzheimer's disease, cognitive decline with age, and other neurodegenerative diseases [12].

The exact mechanisms underlying the association between ApoE4 and these health conditions are not fully understood. However, it is thought that ApoE4 may influence lipid metabolism, vascular function, and inflammation, which contribute to the development and progression of these disorders. ApoE4 may affect the clearance of lipoproteins, leading to dysregulated lipid metabolism and increased accumulation of cholesterol and triglycerides in tissues. This, in turn, may promote inflammation, oxidative stress, and vascular dysfunction, contributing to cardiovascular disease and neurodegenerative processes [13].

Genetic and Functional Characteristics:

There are multiple genetic variations of the ApoE gene, with ApoE4 being the most-studied allele. ApoE4 has cysteine residues at positions 112 and 158, which contribute to its distinctive structural and functional features. ApoE4 has a lower binding affinity for lipoprotein receptors than ApoE2 and ApoE3,

resulting in a decreased clearance of lipoproteins from the circulation. This impairment may contribute to dyslipidemia and increased cardiovascular risk linked with ApoE4 [14].

ApoE4 has also been linked to other cellular functions, in addition to its involvement in lipid metabolism. It participates in synaptic plasticity, neuronal repair, and the clearance of amyloid-beta, a protein implicated in the pathogenesis of Alzheimer's disease. However, the precise mechanisms through which ApoE4 impacts these processes and leads to disease vulnerability remain unknown [15].

3. Vitiligo:

Vitiligo is a chronic, acquired skin illness marked by areas of depigmented or hypopigmented skin, hair, or mucous membranes. These spots are caused by the loss of melanocytes, the pigment-producing cells responsible for skin pigmentation. Vitiligo affects people of various ages, ethnicities, and genders, and its precise aetiology remains complicated and multivariate [16].

Clinical Features:

The clinical appearance of vitiligo is marked by the presence of distinct, pigment-free, milky-white macules or patches. These lesions may occur everywhere on the body, including the face, extremities, trunk, and genital regions. The size and location of the lesions might vary considerably across people, ranging from minor, localised lesions to significant

involvement of broad body surface regions (Fig. (3) [17].



Fig. (3) Clinical presentation of vitiligo [18].

Etiology:

The actual aetiology of vitiligo remains unknown. However, genetic, environmental, immunological, and metabolic variables are considered to be involved. Both genetic predisposition and environmental stimuli seem to play important roles in the development of vitiligo. Many genetic susceptibility loci have been found, showing the involvement of multiple genes involved in immunological modulation, melanocyte function, and oxidative stress response [19].

Possible Mechanisms:

Vitiligo is classified as an autoimmune condition in which the immune system attacks and destroys melanocytes. There is an interaction between genetic predisposition, immunological dysregulation, and environmental stimuli in autoimmune processes. The precise cause of autoimmunity in vitiligo is unknown, although it is believed to include a lack of self-tolerance that causes immune cells to recognise melanocytes as foreign antigens [20].

Emerging evidence in recent years has linked abnormalities in lipid metabolism and oxidative stress in the aetiology of vitiligo.

Lipid metabolism is essential for the maintenance of cellular homeostasis and function. Vitiligo has been associated with alterations in lipid metabolism, including anomalies in cholesterol transport and metabolism. Apolipoprotein E4 (ApoE4), a protein involved in lipid metabolism, has garnered interest as a possible factor in the development or progression of vitiligo. ApoE4 is produced in the liver and functions in the transport and metabolism of lipids, particularly cholesterol [21].

It is speculated that ApoE4 may alter lipid homeostasis, immunological responses, and oxidative stress in melanocytes, however its significance in vitiligo remains unclear. Potentially mediated by ApoE4, dysregulation of lipid metabolism may contribute to the oxidative stress found in vitiligo. Oxidative stress, which is defined by an imbalance between the formation of reactive oxygen species (ROS) and the cellular antioxidant defence systems, has been linked to the damage and loss of melanocytes in vitiligo (Fig. (4) [22].




Fig. (4) Representation of Oxidative Stress (OS) and activation of innate immunity in vitiligo [19].

Active research focuses on the relationship between lipid metabolism, ApoE4, oxidative stress, and autoimmunity in vitiligo. Understanding the probable pathways linking lipid metabolism and ApoE4 in vitiligo may provide light on the pathophysiology of the illness, including the disruption of melanocyte function, immunological dysregulation, and oxidative damage. To establish the specific involvement of lipid metabolism and ApoE4 in vitiligo, as well as their potential as therapeutic targets or diagnostic indicators, more study is required [23].

4. Potential Mechanisms of Apolipoprotein E4 (ApoE4):

Understanding the possible processes via which Apolipoprotein E4 (ApoE4) may impact the aetiology of vitiligo is essential for elucidating the disease's complexity. Multiple lines of evidence show that lipid metabolism and ApoE4 may play a role in melanocyte failure and immunological dysregulation, which are major contributors to the onset and progression of vitiligo [24].

Table (2) Potential Mechanisms by which Apolipoprotein E4 (ApoE4) may Influence the Pathogenesis of Vitiligo [25]

Potential Mechanisms	
Lipid Metabolism	<ul style="list-style-type: none"> - Dysregulation of lipid metabolism may contribute to vitiligo pathogenesis. - Altered lipid homeostasis, potentially mediated by ApoE4, may impact melanocyte function and melanin production. - Disruptions in lipid metabolism can lead to oxidative stress, which may damage melanocytes and contribute to depigmentation in vitiligo. - ApoE4 may interact with lipid rafts in melanocytes, affecting their signaling and metabolic processes.
Melanocyte Dysfunction	<ul style="list-style-type: none"> - Alterations in lipid raft composition and function could disrupt melanocyte homeostasis and contribute to vitiligo development. - ApoE4, with its involvement in neuronal repair mechanisms, may influence the repair capacity and resilience of melanocytes. - Immune dysregulation is a hallmark of vitiligo, and ApoE4 may influence immune responses in the disease.
Immune Dysregulation	<ul style="list-style-type: none"> - Dysregulated lipid metabolism mediated by ApoE4 may disrupt immune cell homeostasis and promote pro-inflammatory responses. - Altered lipid mediators and immune cell activation influenced by ApoE4 could contribute to immune cell infiltration and melanocyte destruction in vitiligo. - ApoE4 may modulate antigen presentation, cytokine production, and T-cell activation, influencing the balance between regulatory and effector immune responses in vitiligo.

1. Lipid Metabolism:

The metabolism of lipids is essential for cellular homeostasis and function. Variations in lipid metabolism have been linked to a number of illnesses, including vitiligo. ApoE4, which is involved in lipid transport and metabolism, may lead to abnormalities in lipid homeostasis that influence the function of melanocytes [26].

It has been postulated that ApoE4-mediated deregulation of lipid metabolism might disturb the balance of lipid components required for proper melanocyte activity. Melanogenesis, the process through which melanocytes create and transport melanin pigments responsible for skin and hair colour, is dependent on lipids. In vitiligo, disturbances in lipid metabolism may influence melanocyte function, limit melanin formation, and lead to pigment loss [11].

Moreover, since lipids are vulnerable to oxidation, lipid dysregulation may contribute to oxidative stress. The aetiology of vitiligo has been linked to oxidative stress, which is defined by an imbalance between the formation of reactive oxygen species (ROS) and cellular antioxidant defence systems. Increased ROS generation and lipid peroxidation may cause melanocyte damage and eventual destruction, hence aggravating vitiligo depigmentation [27].

2. Melanocyte Dysfunction:

ApoE4 may alter melanocyte function directly or indirectly via many methods. ApoE4, an apolipoprotein, has been hypothesised to interact with lipid rafts in the plasma membrane of melanocytes, influencing their signalling and metabolic functions. Changes in the structure and function of lipid rafts may

affect melanocyte homeostasis and contribute to the aetiology of vitiligo [28].

ApoE4 has also been linked in the regulation of neuronal plasticity and repair processes. Melanocytes and neural crest cells have embryological beginnings, and both cell types are susceptible to oxidative stress and immune-mediated damage. Consequently, it is plausible that ApoE4, which is involved in neural repair pathways, may similarly affect the repair ability and resilience of melanocytes [29].

3. Immune Dysregulation:

Immune dysregulation is the defining characteristic of vitiligo, which is distinguished by the invasion of immune cells and the production of an autoimmune reaction against melanocytes. ApoE4's impacts on lipid metabolism and immune cell activity may have the ability to alter immunological responses in vitiligo [30].

Immune cell regulation and activation are tightly tied to lipid metabolism. ApoE4-mediated dysregulated lipid metabolism may disturb immune cell homeostasis and enhance proinflammatory responses. This imbalance may contribute to the activation and migration of immune cells into the skin, resulting in the death of melanocytes [31].

In addition, ApoE4 may modulate antigen presentation, cytokine generation, and T-cell activation to influence immunological responses. Alterations in lipid metabolism and consequent alterations in lipid mediators may affect the equilibrium between regulatory and effector immunological responses, resulting in the breakdown of immune tolerance and the development of autoimmunity against melanocytes [32].

ApoE4 may impact the aetiology of vitiligo by pathways including lipid metabolism, melanocyte dysfunction, and immunological dysregulation. ApoE4-mediated dysregulation of lipid metabolism may affect melanocyte homeostasis, inhibit melanin synthesis, and exacerbate oxidative stress. ApoE4 may have direct or indirect effects on melanocyte function by interacting with lipid rafts and participating in repair pathways. ApoE4 may also influence immunological responses by modulating lipid-mediated immune cell activation and increasing inflammation. Understanding these putative processes is crucial for getting an understanding of the intricate relationship between lipid metabolism, ApoE4, and the pathophysiology of vitiligo [33].

4. Clinical Implications:

The evaluation of changed blood levels of Apolipoprotein E4 (ApoE4) in vitiligo patients may have clinical consequences.

Understanding the clinical importance of ApoE4 levels may help to diagnostic, predictive, and individualised therapeutic methods. Here, we examine the possible clinical ramifications of increased ApoE4 serum levels in vitiligo patients [34].

1. Diagnostic Biomarker:

ApoE4 levels in the blood may act as a diagnostic biomarker for vitiligo. Currently, clinical assessment is used to diagnose vitiligo, which is often supported by Wood's lamp examination, histological study, and autoimmune marker testing. However, these diagnostic methods are limited by subjective interpretation and inability to forecast disease development [35].

The measurement of blood ApoE4 levels may serve as a further objective diagnostic tool. In combined with other diagnostic criteria, elevated or reduced ApoE4 levels might lead to a more accurate and efficient diagnosis of vitiligo. Integrating ApoE4 measurement into the diagnostic procedure may improve diagnosis accuracy and assist differentiate vitiligo from other depigmentation illnesses or ailments with comparable clinical presentations [36].

2. Prognostic Biomarker:

Alterations in ApoE4 serum levels may have prognostic consequences for vitiligo. Vitiligo is an illness with a diverse nature, and the disease history may vary considerably across people. Predicting the course and prognosis of a disease remains difficult. Identification of biomarkers that may provide light on the progression and prognosis of a disease is of significant clinical interest [37].

The results of studies examining the relationship between ApoE4 levels and vitiligo development might be informative. Monitoring ApoE4 levels over time may aid in predicting the probability of disease development, the degree of depigmentation, and the possible therapeutic response. Patients with a higher ApoE4 concentration may be at a greater risk for illness progression or disease involvement. ApoE4-based prognostic classification might guide treatment choices and allow individualised management methods [38, 39].

3. Personalized Treatment Approaches:

Changes in serum ApoE4 levels may potentially have ramifications for individualised vitiligo treatment techniques. Currently, there is no uniformly effective medicine for vitiligo, making treatment difficult. Individualized therapy approaches that take into account patient-specific traits, disease subtypes, and underlying pathogenic processes have the potential to enhance patient outcomes [40].

ApoE4, as a possible regulator of lipid metabolism and immunological responses, might provide light on the underlying illness processes of certain individuals. Determining the ApoE4 status of patients may aid in the identification of subgroups that are more likely to respond favourably to certain treatment regimens. Patients with excessive ApoE4 levels may benefit from medicines that target lipid metabolism or antioxidant pathways, while individuals with lower ApoE4 levels may need interventions that modulate the immune system. Such tailored therapy methods, informed by ApoE4 levels, might increase patient satisfaction and maximise therapeutic results [41].

4. Conclusions:

The potential clinical implications of altered serum levels of ApoE4 in vitiligo are promising. ApoE4 assessment holds the potential to serve as a diagnostic biomarker, aiding in accurate and objective diagnosis. Additionally, ApoE4 levels may have prognostic value, helping predict disease progression and inform treatment decisions. Furthermore, ApoE4 evaluation could contribute to personalized treatment approaches, guiding therapeutic interventions based on individual ApoE4 status.

However, it is important to acknowledge the limitations of the current studies, including small sample sizes, lack of standardization, and the need for larger-scale studies, longitudinal investigations, and functional experiments. Addressing these limitations and pursuing further research will provide a more comprehensive understanding of the relationship between ApoE4 and vitiligo, as well as its clinical implications.

Assessing serum levels of ApoE4 in patients with vitiligo represents a promising avenue for advancing our understanding of the disease and developing novel therapeutic strategies. Integration of ApoE4 assessment into clinical practice could enhance diagnostic accuracy, prognostic predictions, and personalized treatment approaches for vitiligo patients. Furthermore, elucidating the underlying molecular mechanisms by which ApoE4 influences melanocyte dysfunction and immune dysregulation may reveal novel targets for therapeutic intervention.

References

- [1] W.L. Chang, W.R. Lee, Y.C. Kuo, Y.H. Huang. Vitiligo: An Autoimmune Skin Disease and its Immunomodulatory Therapeutic Intervention. *Front Cell Dev Biol*;9:797026. 2021
- [2] B.K. Khaitan, T. Sindhuja. Autoimmunity in vitiligo: Therapeutic implications and opportunities. *Autoimmun Rev*;21:102932. 2022
- [3] S. Patel, A. Rauf, H. Khan, B.R. Meher, S.S.U. Hassan. A holistic review on the autoimmune disease vitiligo with emphasis on the causal factors. *Biomed Pharmacother*;92:501-8. 2017
- [4] C. Krüger, K.U. Schallreuter. A review of the worldwide prevalence of vitiligo in children/adolescents and adults. *Int J Dermatol*;51:1206-12. 2012
- [5] A.C. Raulin, S.V. Doss, Z.A. Trotter, T.C. Ikezu, G. Bu, C.C. Liu. ApoE in Alzheimer's disease: pathophysiology and therapeutic strategies. *Mol Neurodegener*;17:72. 2022
- [6] D.A. Butterfield, M.P. Mattson. Apolipoprotein E and oxidative stress in brain with relevance to Alzheimer's disease. *Neurobiol Dis*;138:104795. 2020
- [7] M.A. Husain, B. Laurent, M. Plourde. APOE and Alzheimer's Disease: From Lipid Transport to Physiopathology and Therapeutics. *Front Neurosci*;15:630502. 2021
- [8] C.Y. Chou, Y.L. Lin, Y.C. Huang, S.Y. Sheu, T.H. Lin, H.J. Tsay, et al. Structural variation in human apolipoprotein E3 and E4: secondary structure, tertiary structure, and size distribution. *Biophys J*;88:455-66. 2005
- [9] C.C. Liu, C.C. Liu, T. Kanekiyo, H. Xu, G. Bu. Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. *Nat Rev Neurol*;9:106-18. 2013
- [10] A.D. Marais. Apolipoprotein E in lipoprotein metabolism, health and cardiovascular disease. *Pathology*;51:165-76. 2019
- [11] G. Qi, Y. Mi, X. Shi, H. Gu, R.D. Brinton, F. Yin. ApoE4 Impairs Neuron-Astrocyte Coupling of Fatty Acid Metabolism. *Cell Rep*;34:108572. 2021
- [12] Y. Yamazaki, N. Zhao, T.R. Caulfield, C.C. Liu, G. Bu. Apolipoprotein E and Alzheimer disease: pathobiology and targeting strategies. *Nat Rev Neurol*;15:501-18. 2019
- [13] S. Parhizkar, D.M. Holtzman. APOE mediated neuroinflammation and neurodegeneration in Alzheimer's

- disease. *Semin Immunol*;59:101594. 2022
- [14] J. Alagarsamy, A. Jaeschke, D.Y. Hui. Apolipoprotein E in Cardiometabolic and Neurological Health and Diseases. *Int J Mol Sci*;23. 2022
- [15] H.C. Hunsberger, P.D. Pinky, W. Smith, V. Suppiramaniam, M.N. Reed. The role of APOE4 in Alzheimer's disease: strategies for future therapeutic interventions. *Neuronal Signal*;3:Ns20180203. 2019
- [16] A. Frączek, A. Owczarczyk-Saczonek, W. Placek. The Role of T(RM) Cells in the Pathogenesis of Vitiligo-A Review of the Current State-Of-The-Art. *Int J Mol Sci*;21. 2020
- [17] G. Iannella, A. Greco, D. Didona, B. Didona, G. Granata, A. Manno, et al. Vitiligo: Pathogenesis, clinical variants and treatment approaches. *Autoimmun Rev*;15:335-43. 2016
- [18] V.K. Mahajan, S. Vashist, P.S. Chauhan, K.I.S. Mehta, V. Sharma, A. Sharma. Clinico-Epidemiological Profile of Patients with Vitiligo: A Retrospective Study from a Tertiary Care Center of North India. *Indian Dermatol Online J*;10:38-44. 2019
- [19] H.Z. Marchioro, C.C. Silva de Castro, V.M. Fava, P.H. Sakiyama, G. Dellatorre, H.A. Miot. Update on the pathogenesis of vitiligo. *An Bras Dermatol*;97:478-90. 2022
- [20] E.L. Katz, J.E. Harris. Translational Research in Vitiligo. *Front Immunol*;12:624517. 2021
- [21] W.L. Chang, C.H. Ko. The Role of Oxidative Stress in Vitiligo: An Update on Its Pathogenesis and Therapeutic Implications. *Cells*;12. 2023
- [22] C.G. Fernandez, M.E. Hamby, M.L. McReynolds, W.J. Ray. The Role of APOE4 in Disrupting the Homeostatic Functions of Astrocytes and Microglia in Aging and Alzheimer's Disease. *Front Aging Neurosci*;11:14. 2019
- [23] J.P. Strassner, J.E. Harris. Understanding mechanisms of autoimmunity through translational research in vitiligo. *Curr Opin Immunol*;43:81-8. 2016
- [24] Y.Y. Sun, Z. Wang, H.C. Huang. Roles of ApoE4 on the Pathogenesis in Alzheimer's Disease and the Potential Therapeutic Approaches. *Cell Mol Neurobiol*:1-22. 2023
- [25] C. Lyu, Y. Sun. Immunometabolism in the pathogenesis of vitiligo. *Front Immunol*;13:1055958. 2022
- [26] A.N. Lazar, L. Hanbouch, L. Boussicaut, B. Fourmaux, P. Daira, M.J. Millan, et al. Lipid Dys-Homeostasis Contributes to APOE4-Associated AD Pathology. *Cells*;11. 2022
- [27] J. Pleńkowska, M. Gabig-Cimińska, P. Mozolewski. Oxidative Stress as an Important Contributor to the Pathogenesis of Psoriasis. *Int J Mol Sci*;21. 2020
- [28] S.I. Lee, W. Jeong, H. Lim, S. Cho, H. Lee, Y. Jang, et al. APOE4-carrying human astrocytes oversupply cholesterol to promote neuronal lipid raft expansion and A β generation. *Stem Cell Reports*;16:2128-37. 2021
- [29] L. Zhang, Y. Xia, Y. Gui. Neuronal ApoE4 in Alzheimer's disease and potential therapeutic targets. *Front Aging Neurosci*;15:1199434. 2023
- [30] H.Z. Long, Z.W. Zhou, Y. Cheng, H.Y. Luo, F.J. Li, S.G. Xu, et al. The Role of Microglia in Alzheimer's Disease From the Perspective of Immune Inflammation and Iron Metabolism. *Front Aging Neurosci*;14:888989. 2022
- [31] M.J. Hubler, A.J. Kennedy. Role of lipids in the metabolism and activation of immune cells. *J Nutr Biochem*;34:1-7. 2016
- [32] N. Wang, M. Wang, S. Jeevaratnam, C. Rosenberg, T.C. Ikezu, F. Shue, et al. Opposing effects of apoE2 and apoE4 on microglial activation and lipid metabolism in response to demyelination. *Mol Neurodegener*;17:75. 2022
- [33] J. Chen, S. Li, C. Li. Mechanisms of melanocyte death in vitiligo. *Med Res Rev*;41:1138-66. 2021
- [34] S. Emrani, H.A. Arain, C. DeMarshall, T. Nuriel. APOE4 is associated with cognitive and pathological heterogeneity in patients with Alzheimer's disease: a systematic review. *Alzheimers Res Ther*;12:141. 2020
- [35] R. Speeckaert, M. Speeckaert, S. De Schepper, N. van Geel. Biomarkers of disease activity in vitiligo: A systematic review. *Autoimmun Rev*;16:937-45. 2017

- [36] R. Simon, M. Girod, C. Fonbonne, A. Salvador, Y. Clément, P. Lanteri, et al. Total ApoE and ApoE4 isoform assays in an Alzheimer's disease case-control study by targeted mass spectrometry (n=669): a pilot assay for methionine-containing proteotypic peptides. *Mol Cell Proteomics*;11:1389-403. 2012
- [37] F. Lin, W. Hu, W. Xu, M. Zhou, A.E. Xu. CXCL9 as a key biomarker of vitiligo activity and prediction of the success of cultured melanocyte transplantation. *Sci Rep*;11:18298. 2021
- [38] A. Vipin, D. Kumar, S.A. Soo, F.Z. Zailan, Y.J. Leow, C.L. Koh, et al. APOE4 carrier status determines association between white matter disease and grey matter atrophy in early-stage dementia. *Alzheimers Res Ther*;15:103. 2023
- [39] L.S. Elias-Sonnenschein, W. Viechtbauer, I.H. Ramakers, F.R. Verhey, P.J. Visser. Predictive value of APOE-ε4 allele for progression from MCI to AD-type dementia: a meta-analysis. *J Neurol Neurosurg Psychiatry*;82:1149-56. 2011
- [40] S. Ghashghaei, M. Abbaszadeh, S. Karimi, L. Ataie-Fashtami, A. Bajouri, M. Vosough. Advanced Therapy Medicinal Products in Vitiligo; Current Status, Future Prospect, and Approved Treatments. *Cell J*;25:143-57. 2023
- [41] A.R. Garcia, C. Finch, M. Gatz, T. Kraft, D. Eid Rodriguez, D. Cummings, et al. APOE4 is associated with elevated blood lipids and lower levels of innate immune biomarkers in a tropical Amerindian subsistence population. *Elife*;10. 2021